ArticleCancer immunology, immunotherapy : CII2026
Clinical and immunological implications of lymphocyte-activation gene 3 expression in metastatic colorectal cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Colorectal cancer liver metastases: mechanism and therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLymphocyte-activation gene 3 (LAG3), an inhibitory immune checkpoint receptor, has emerged as a potential therapeutic target in various cancer, including colorectal cancer (CRC). However, its prognostic role and immunologic context in metastatic CRC (mCRC) remain unclear. This study investigated the prognostic impact of LAG3 expression and its biological role within the mCRC immune microenvironment.
methodsLAG3 expression was evaluated by immunohistochemistry in primary and/or metastatic tumors from a retrospective mCRC cohort. Associations between LAG3 expression, clinicopathological features, and overall survival were analyzed and validated using data from The Cancer Genome Atlas (TCGA) COADREAD cohort. Transcriptomic data from TCGA and single-cell RNA sequencing data from 23 Korean CRC samples were used to explore pathway enrichment and cell-cell interactions.
resultsA total of 144 mCRC patients were included. Primary tumors showed higher LAG3 expression than metastatic tumors, with right-sided and liver metastases exhibiting the highest level. Both univariate and multivariate analyses revealed that LAG3 expression was an independent prognostic biomarker of mCRC, validated in the TCGA COADREAD cohort. Transcriptomic analysis revealed significant correlations between LAG3 expression and angiogenesis, epithelial-mesenchymal transition, and TGF-β signaling pathways, which were linked to immunosuppressive microenvironment and poor prognosis. Cell-cell communication analysis showed CD8⁺ T cells interact with various cell subpopulations, with Galectin-9-TIM-3 signaling uniquely present in LAG3⁺CD8⁺ T cells.
conclusionsLAG3 expression is an independent prognostic biomarker of mCRC. The distinct Galectin-9-TIM-3 signaling in LAG3⁺CD8⁺ T cells may contribute to limited therapeutic efficacy of LAG3 blockade, suggesting potential combinational immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.